Global Human Microbiome Therapeutics Market 2018-2022 - Product Image

Global Human Microbiome Therapeutics Market 2018-2022

  • ID: 4439522
  • Report
  • Region: Global
  • 106 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • Bristol-Myers Squibb
  • ENTEROME Bioscience
  • Johnson & Johnson
  • Rebiotix
  • Seres Therapeutics
  • Takeda Pharmaceutical
  • MORE
About Human Microbiome Therapeutics

Microbiome Therapeutics is developing evidence-based microbiome modulators designed to shift bacterial populations and their environment in the gastrointestinal (GI) tract to better manage serious health conditions. GIT is an organ system that includes the mouth, esophagus, stomach, and the intestines. The GIT can be divided into upper Git and lower GIT. Upper GIT consists of the oral cavity, the pharynx, the esophagus, the stomach, and the duodenum. The lower GIT consists of the small and large intestines. Gastrointestinal disorders refer to diseases involving the GIT. Microbiome therapeutics are being increasingly adopted for the treatment of gastrointestinal disorders such as IBS and ulcerative colitis.

The analysts forecast the global human microbiome therapeutics market to grow at a CAGR of 14.19% during the period 2018-2022.

Covered in this report
The report covers the present scenario and the growth prospects of the global human microbiome therapeutics market for 2018-2022. To calculate the market size, the report considers the revenue generated from the sales of human microbiome therapeutics.

The market is divided into the following segments based on geography:
  • Americas
  • APAC
  • EMEA
The report, Global Human Microbiome Therapeutics market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

key vendors
  • ENTEROME Bioscience
  • Rebiotix
  • Seres Therapeutics
  • Vedanta Biosciences
Other prominent vendors
  • Bristol-Myers Squibb
  • Johnson & Johnson
  • Takeda Pharmaceutical
Market drivers
  • Side effects of the existing treatments
  • For a full, detailed list, view the full report
Market trends
  • Growing investments from venture capitalists
  • For a full, detailed list, view the full report
Key questions answered in this report
  • What will the market size be in 2022 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Bristol-Myers Squibb
  • ENTEROME Bioscience
  • Johnson & Johnson
  • Rebiotix
  • Seres Therapeutics
  • Takeda Pharmaceutical
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: INTRODUCTION
  • Market outline
PART 05: MARKET LANDSCAPE
  • Market ecosystem
  • Market segmentation analysis
PART 06: MARKET SIZING
  • Market definition
  • Market size and forecast
PART 07: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 08: PIPELINE LANDSCAPE

PART 09: MARKET SEGMENTATION BY THERAPEUTIC APPLICATION
  • Comparison by therapeutic application
  • Gastrointestinal disorders
  • Immunological conditions
  • Others
  • Market opportunity by therapeutic application
PART 10: CUSTOMER LANDSCAPE

PART 11: REGIONAL LANDSCAPE
  • Comparison by region
  • Human microbiome therapeutics market in Americas
  • Human microbiome therapeutics market in EMEA
  • Human microbiome therapeutics market in APAC
  • Key leading countries
  • Market opportunity by region
PART 12: DECISION FRAMEWORK

PART 13: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 14: MARKET TRENDS
  • Increase in industry-academia collaboration
  • Increasing investments by venture capitalists
PART 15: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
  • Competitive analysis
PART 16: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • ENTEROME Bioscience
  • Rebiotix
  • Seres Therapeutics
  • Vedanta Biosciences
PART 17: APPENDIX
  • List of abbreviations
List of Exhibits
Exhibit 01: Microbiome by host
Exhibit 02: Common prebiotics
Exhibit 03: Major sources of prebiotics
Exhibit 04: Benefits of probiotics
Exhibit 05: Parent market
Exhibit 06: Global human microbiome therapeutics market: Characteristics
Exhibit 07: Global human microbiome therapeutics market: Segmentation
Exhibit 08: Market definition: Inclusions and exclusions checklist
Exhibit 09: Market size 2017
Exhibit 10: Validation techniques employed for market sizing 2017
Exhibit 11: Global human microbiome therapeutics market 2017-2022 ($ millions)
Exhibit 12: Global human microbiome therapeutics market: Year-over-year growth
Exhibit 13: Five forces analysis 2017
Exhibit 14: Five forces analysis 2022
Exhibit 15: Bargaining power of buyers
Exhibit 16: Bargaining power of suppliers
Exhibit 17: Threat of new entrants
Exhibit 18: Threat of substitutes
Exhibit 19: Threat of rivalry
Exhibit 20: Market condition: Five forces 2017
Exhibit 21: Pipeline landscape
Exhibit 22: Key clinical trials
Exhibit 23: Global human microbiome therapeutics market by therapeutic application 2017-2022 (% share)
Exhibit 24: Comparison by therapeutic application
Exhibit 25: Global human microbiome therapeutics market by gastrointestinal disorders 2017-2022 ($ millions)
Exhibit 26: Global human microbiome therapeutics market by gastrointestinal disorders: Year-over-year growth 2018-2022
Exhibit 27: Global human microbiome therapeutics market by immunological conditions 2017-2022 ($ millions)
Exhibit 28: Global human microbiome therapeutics market by immunological conditions: Year-over-year growth 2018-2022
Exhibit 29: Global human microbiome therapeutics market by others 2017-2022 ($ millions)
Exhibit 30: Global human microbiome therapeutics market by others: Year-over-year growth 2018-2022
Exhibit 31: Market opportunity by therapeutic application
Exhibit 32: Customer landscape
Exhibit 33: Global human microbiome therapeutics market by region 2017-2022 (% share)
Exhibit 34: Regional comparison
Exhibit 35: Human microbiome therapeutics market in Americas 2017-2022 ($ millions)
Exhibit 36: Human microbiome therapeutics market in Americas: Year-over-year growth
Exhibit 37: Human microbiome therapeutics market in EMEA 2017-2022 ($ millions)
Exhibit 38: Human microbiome therapeutics market in EMEA: Year-over-year growth 2018-2022
Exhibit 39: Human microbiome therapeutics market in APAC 2017-2022 ($ millions)
Exhibit 40: Human microbiome therapeutics market in APAC: Year-over-year growth 2018-2022
Exhibit 41: Top Asian countries in terms of population with diabetes (millions)
Exhibit 42: Key leading countries
Exhibit 43: Market opportunity by region
Exhibit 44: Global obesity facts 2014
Exhibit 45: Factors causing changes in human microbiome
Exhibit 46: Antibiotic resistance steps
Exhibit 47: Vendor landscape
Exhibit 48: Landscape disruption
Exhibit 49: Competitive structure analysis of global microbiome therapeutics market
Exhibit 50: Vendors covered
Exhibit 51: Vendor classification
Exhibit 52: Market positioning of vendors
Exhibit 53: ENTEROME Bioscience: Overview
Exhibit 54: ENTEROME Bioscience: Business segments
Exhibit 55: ENTEROME Bioscience: Organizational developments
Exhibit 56: ENTEROME Bioscience: Geographic focus
Exhibit 57: ENTEROME Bioscience: Segment focus
Exhibit 58: ENTEROME Bioscience: Key offerings
Exhibit 59: Rebiotix: Overview
Exhibit 60: Rebiotix: Business segments
Exhibit 61: Rebiotix: Organizational developments
Exhibit 62: Rebiotix: Geographic focus
Exhibit 63: Rebiotix: Segment focus
Exhibit 64: Rebiotix: Key offerings
Exhibit 65: Seres Therapeutics: Overview
Exhibit 66: Seres Therapeutics: Business segments
Exhibit 67: Seres Therapeutics: Organizational developments
Exhibit 68: Seres Therapeutics: Geographic focus
Exhibit 69: Seres Therapeutics: Segment focus
Exhibit 70: Seres Therapeutics: Key offerings
Exhibit 71: Vedanta Biosciences: Overview
Exhibit 72: Vedanta Biosciences: Business segments
Exhibit 73: Vedanta Biosciences: Organizational developments
Exhibit 74: Vedanta Biosciences: Geographic focus
Exhibit 75: Vedanta Biosciences: Segment focus
Exhibit 76: Vedanta Biosciences: Key offerings
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Bristol-Myers Squibb
  • ENTEROME Bioscience
  • Johnson & Johnson
  • Rebiotix
  • Seres Therapeutics
  • Takeda Pharmaceutical
  • MORE
New Report Released: – Global Human Microbiome Therapeutics market 2018-2022

The author of the report recognizes the following companies as the key players in the global human microbiome therapeutics market: ENTEROME Bioscience, Rebiotix, Seres Therapeutics, and Vedanta Biosciences.

Other Prominent Vendors in the market are: Bristol-Myers Squibb, Johnson & Johnson, and Takeda Pharmaceutical.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is growing investments from venture capitalists. Venture capitalists are capitalizing on the need for effective treatment and are offering therapeutic treatment solutions to treat disorders such as autoimmune disorders, infections, and cancer. Investments from venture capitalists towards microbiome therapeutics is exponentially boosting the growth of the microbiome sequencing therapeutics market. Vedanta Biosciences is already collaborating with NYU Langone Medical Center to develop novel microbiome- derived immunotherapies for cancer patients.”

According to the report, one of the major drivers for this market is side effects of the existing treatments. Various medicines available in the market have several side-effects including minor headaches. These medicines may also impart serious side-effects such as liver or kidney injury, heart problems, and even death. The seriousness of side-effects drives the need for innovative treatment technologies, such as human microbiome therapeutics, that have reduced the negative impact on the human body. The demand for microbiome therapeutics is increasing since it provides treatment sans chemicals.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • ENTEROME Bioscience
  • Rebiotix
  • Seres Therapeutics
  • Vedanta Biosciences
  • Bristol-Myers Squibb
  • Johnson & Johnson
  • Takeda Pharmaceutical
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll